TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Stratified, Double-Blind, Placebo-Controlled Phase 2 Study of Steroid-Sparing Properties of Sargramostim (Leukine) Therapy in Patients With Cortico-Dependent Crohn's Disease
Brief Summary: The purpose of this study is to evaluate the effectiveness of Leukine to decrease the need for steroid treatment for Crohn's disease.


Options:
A: Arm Label: control = conventional treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Immunossuppresive treatment; Type: EXPERIMENTAL; Interventions: Drug: early immunosuppressants (azathioprine, methotrexate) | Intervention Type: DRUG; Name: early immunosuppressants (azathioprine, methotrexate); Assigned to Arm(s): Immunossuppresive treatment
B: Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Sargramostim (Leukine) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sargramostim (Leukine); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
D: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Trial of Primary Prophylaxis Against Joint Disease in Children With Severe Hemophilia
Brief Summary: This study examines the progression of joint disease in children with hemophilia assigned to either standard treatment or enhanced therapy.


Options:
A: N/A
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Cohort 1, Cohort 2 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Cohort 1, Cohort 2
C: Arm Label: Group 1; Type: OTHER; Interventions: Genetic: Gene Transfer, Drug: scAAV2/8-LP1-hFIXco | Intervention Type: GENETIC; Name: Gene Transfer; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: scAAV2/8-LP1-hFIXco; Assigned to Arm(s): Group 1
D: Arm Label: Arm C (Control): No Prophylaxis, Then Emicizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Emicizumab, Drug: Factor VIII (FVIII) | Arm Label: Arm A: Emicizumab 1.5 mg/kg QW; Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: Factor VIII (FVIII) | Arm Label: Arm B: Emicizumab 3 mg/kg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: Factor VIII (FVIII) | Arm Label: Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis); Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: Factor VIII (FVIII) | Intervention Type: DRUG; Name: Emicizumab; Assigned to Arm(s): Arm A: Emicizumab 1.5 mg/kg QW, Arm B: Emicizumab 3 mg/kg Q2W, Arm C (Control): No Prophylaxis, Then Emicizumab, Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Intervention Type: DRUG; Name: Factor VIII (FVIII); Assigned to Arm(s): Arm A: Emicizumab 1.5 mg/kg QW, Arm B: Emicizumab 3 mg/kg Q2W, Arm C (Control): No Prophylaxis, Then Emicizumab, Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Trial of Primary Prophylaxis Against Joint Disease in Children With Severe Hemophilia
Brief Summary: This study examines the progression of joint disease in children with hemophilia assigned to either standard treatment or enhanced therapy.


Options:
A: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): On-demand
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Cohort 1, Cohort 2 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Cohort 1, Cohort 2
C: N/A
D: Arm Label: Fixed Weekly Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc), Drug: rFIX | Arm Label: Individualized Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: On Demand; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: Surgery; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Intervention Type: DRUG; Name: Factor IX (rFIXFc); Assigned to Arm(s): Fixed Weekly Interval, Individualized Interval, On Demand, Surgery | Intervention Type: DRUG; Name: rFIX; Assigned to Arm(s): Fixed Weekly Interval

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Trial of Primary Prophylaxis Against Joint Disease in Children With Severe Hemophilia
Brief Summary: This study examines the progression of joint disease in children with hemophilia assigned to either standard treatment or enhanced therapy.


Options:
A: Arm Label: Arm A: 1.5 mg/kg Emicizumab QW; Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: rFVIIa, Drug: aPCC | Arm Label: Arm B (Control): No Prophylaxis, Then Emicizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Emicizumab, Drug: rFVIIa, Drug: aPCC | Arm Label: Arm C: 1.5 mg/kg Emicizumab QW; Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: rFVIIa, Drug: aPCC | Arm Label: Arm D: 1.5 mg/kg Emicizumab QW; Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: rFVIIa, Drug: aPCC | Intervention Type: DRUG; Name: Emicizumab; Assigned to Arm(s): Arm A: 1.5 mg/kg Emicizumab QW, Arm B (Control): No Prophylaxis, Then Emicizumab, Arm C: 1.5 mg/kg Emicizumab QW, Arm D: 1.5 mg/kg Emicizumab QW | Intervention Type: DRUG; Name: rFVIIa; Assigned to Arm(s): Arm A: 1.5 mg/kg Emicizumab QW, Arm B (Control): No Prophylaxis, Then Emicizumab, Arm C: 1.5 mg/kg Emicizumab QW, Arm D: 1.5 mg/kg Emicizumab QW | Intervention Type: DRUG; Name: aPCC; Assigned to Arm(s): Arm A: 1.5 mg/kg Emicizumab QW, Arm B (Control): No Prophylaxis, Then Emicizumab, Arm C: 1.5 mg/kg Emicizumab QW, Arm D: 1.5 mg/kg Emicizumab QW
B: N/A
C: Arm Label: rFIXFc Prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: rFIXFc, Drug: FIX | Intervention Type: DRUG; Name: rFIXFc; Assigned to Arm(s): rFIXFc Prophylaxis | Intervention Type: DRUG; Name: FIX; Assigned to Arm(s): rFIXFc Prophylaxis
D: Arm Label: Pharmacokinetic (PK) evaluation of BAX 855; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Arm Label: FVIII trough target 1-3%; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Arm Label: FVIII trough target 8-12%; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Pharmacokinetic (PK) evaluation of BAX 855 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): FVIII trough target 1-3% | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): FVIII trough target 8-12%

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate long-term safety information of infliximab in patients who have participated in infliximab clinical studies in ulcerative colitis.


Options:
A: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
C: Arm Label: Infliximab 5 mg/kg; Type: N/A; Interventions: Drug: Infliximab 5 mg/kg | Arm Label: Infliximab 10 mg/kg; Type: N/A; Interventions: Drug: Infliximab 10 mg/kg | Arm Label: Placebo; Type: N/A; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab 5 mg/kg; Assigned to Arm(s): Infliximab 5 mg/kg | Intervention Type: DRUG; Name: Infliximab 10 mg/kg; Assigned to Arm(s): Infliximab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Open-label Abatacept (ABA)-Previous User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Arm Label: Open-label ABA-Current User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Drug: Anti-Tumor Necrosing Factor (TNF) Therapy | Arm Label: Long-term ABA; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD); Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Anti-Tumor Necrosing Factor (TNF) Therapy; Assigned to Arm(s): Open-label ABA-Current User

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy
Brief Summary: A study of the safety and efficacy of Infliximab (Remicade) versus placebo in subjects with Ankylosing Spondylitis


Options:
A: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate
B: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): N/A
D: Arm Label: Anakinra; Type: EXPERIMENTAL; Interventions: Drug: Intra-articular metHuIL-1ra (anakinra) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Intra-articular metHuIL-1ra (anakinra); Assigned to Arm(s): Anakinra | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy
Brief Summary: A study of the safety and efficacy of Infliximab (Remicade) versus placebo in subjects with Ankylosing Spondylitis


Options:
A: Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Golimumab (placebo group) | Arm Label: Golimumab; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab | Intervention Type: DRUG; Name: Golimumab (placebo group); Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept/placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: etanercept/placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.


Options:
A: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tezepelumab 700 mg; Type: EXPERIMENTAL; Interventions: Biological: Tezepelumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tezepelumab; Assigned to Arm(s): Tezepelumab 700 mg
C: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B
D: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Biological: IMA-638 is a biologic | Intervention Type: BIOLOGICAL; Name: IMA-638 is a biologic; Assigned to Arm(s): 1
B: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: OCS (prednisone/prednisolone) | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: OCS (prednisone/prednisolone); Assigned to Arm(s): Mepolizumab, Placebo
C: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CAT-354 150 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 150 mg | Arm Label: CAT-354 300 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 300 mg | Arm Label: CAT-354 600 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 600 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 150 mg; Assigned to Arm(s): CAT-354 150 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 300 mg; Assigned to Arm(s): CAT-354 300 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 600 mg; Assigned to Arm(s): CAT-354 600 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.


Options:
A: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a
B: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
D: Arm Label: Anakinra; Type: EXPERIMENTAL; Interventions: Drug: Intra-articular metHuIL-1ra (anakinra) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Intra-articular metHuIL-1ra (anakinra); Assigned to Arm(s): Anakinra | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Autologous peripheral blood stem cell (PBSC) transplantation is now considered standard therapy in patients (\< 65 ans) with multiple myeloma. The Intergroupe Francophone du Myelome conducted a randomised trial of the treatment of multiple myeloma with high dose chemotherapy followed by either one or two successive autologous stem cell transplantation. The probabilities of event-free-survival and overall survival were doubled with a double transplant. The benefits were greatest among patients who had not had a very good partial response to the first transplant.

The aim of this multicenter randomised trial in previously untreated patients with multiple myelome (stage II, III DS)is to assess the optimal timing of a second autologous stem-cell transplant.After a first-line therapy with thalidomide-dexamethasone followed by a PBSC collection, patients are randomly assigned to receive two autologous PBSC transplants (arm A)or one autologous PBSC transplant followed by a consolidation therapy with thalidomide-dexamethasone (arm B). Patients included in the arm B will receive a second transplant in case of disease progression on consolidation therapy, or in case of relapse in responders.


Options:
A: Arm Label: VTD; Type: EXPERIMENTAL; Interventions: Drug: Velcade, Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Arm Label: TD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): VTD | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): TD, VTD | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell (PBSC) collection; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: First Autologous Transplantation; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Second Autologous Transplantation; Assigned to Arm(s): TD, VTD
B: Intervention Type: DRUG; Name: Alternating chemotherapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Autologous Transplantation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Maintenance; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Second transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: ALOGENIC MINI TRASPLANTATION; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: autologous PBSC transplant; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): N/A

Answer: C